Cablivi (caplacizumab-yhdp) – To treat adult patients with acquired thrombotic thrombocytopenic purpura (aTTP).
CABLIVI DOSAGE AND ADMINISTRATION
• CABLIVI should be administered upon the initiation of plasma exchange therapy. The recommended dose of CABLIVI is as follows:
–> First day of treatment: 11 mg bolus intravenous injection at least 15 minutes prior to plasma exchange followed by an 11 mg subcutaneous injection after completion of plasma exchange on day 1.
–> Subsequent treatment during daily plasma exchange: 11 mg subcutaneous injection once daily following plasma exchange.
–> Treatment after the plasma exchange period: 11 mg subcutaneous injection once daily for 30 days beyond the last plasma exchange.
–> If after initial treatment course, sign(s) of persistent underlying disease such as suppressed ADAMTS13 activity levels remain present, treatment may be extended for a maximum of 28 days.
–> Discontinue CABLIVI if the patient experiences more than 2 recurrences of aTTP, while on CABLIVI.
• The first dose should be administered by a healthcare provider as a bolus intravenous injection. Administer subsequent doses subcutaneously in the abdomen.
CABLIVI INDICATIONS AND USAGE
CABLIVI is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
CABLIVI ADVERSE REACTIONS
The most common adverse reactions (>15% of patients) were epistaxis, headache and gingival bleeding.
CABLIVI DRUG INTERACTIONS
Concomitant use of anticoagulants with CABLIVI may increase the risk of bleeding. Monitor closely for bleeding with concomitant use